Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China to Invest 8.8b in Food, Drug Monitoring (China)

This article was originally published in PharmAsia News

Executive Summary

China will invest 8.8 billion yuan ($1.73 billion) in the next three to five years on infrastructure for a nationwide food and drug safety system. The central government will provide 6.3 billion yuan and local governments will invest 2.5 billion yuan to build new centers, buy equipment and connect branches. As part of the effort, the National Institute for the Control of Pharmaceutical and Biological Products in Beijing will be relocated and rebuilt, as will 18,000-square-meter biological labs in the drug control institutes in 16 ports. A monitoring system will be established for the adverse reactions of drugs that will link a national center with 31 local branches. A government official said the country needs three to five years to implement the project to put food and drug safety in line with the country's economic and social development. SFDA also outlined several key tasks in enhancing supervision of food and drugs, especially medical equipment, for the rest of this year. China will also crack down on Web sites illegally selling medicines and health products after a spate of consumer goods scandals intensified trade friction with the United States (Click here for more

You may also be interested in...

People On The Move: Appointments At RB, GSCF And CMDh

Reckitt hires chief digital officer from Nestlé and shakes up Australia leadership; GSCF names Bayer's Schipper as chair; and Europe's CMDh appoints a new chair.

Financing: Q3 Roundup Shows Fall In Device Company Activity But A Rise In IVDs

During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.

Podcast: CBD In Europe – The State Of Play Today

HBW Insight editors David Ridley and Tom Gallen discuss the current state of play concerning cannabidiol dietary supplements regulation in Europe, and find out what consumer health companies need to know according to CBD expert Greer Deal from Global Regulatory Service. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts